Durata Therapeutics, Inc.  (DRTX) Release: Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting  
4/29/2013 11:43:09 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from a Phase 1 study of its lead product candidate, dalbavancin, under investigation for the treatment of susceptible gram positive bacterial infections including MRSA. The data, presented at the 23rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), demonstrate that dalbavancin, when administered to healthy subjects as an IV infusion weekly for a total of up to 8 weeks, was well tolerated.

Help employers find you! Check out all the jobs and post your resume.